logo

For the Inventor, By the Inventor

Basel, Switzerland

Clive McCarthy

This inventor holds 24 USPTO granted patents and 2 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Novartis Ag, Enterprise Therapeutics Limited, Orca Pharmaceuticals Limited. Active years: 2007-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clive McCarthy. Retrieved from https://idiyas.com/inventor/clive-mccarthy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24 

% Patents Active = 33.3

 

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 40(Granted Patents)


Location History:

  • Basel, CH (2007 - 2012)
  • Froidefontaine, FR (2013)
  • Horsham, GB (2014)
  • Oxfordshire, GB (2014 - 2018)
  • Brighton, GB (2020 - 2022)
  • Abingdon, GB (2013 - 2023)

Company Filing History:

goldMedal17 out of 3,978 
 
Novartis Ag
 patents
silverMedal4 out of 6 
 
Enterprise Therapeutics Limited
 patents
bronzeMedal3 out of 3 
 
Orca Pharmaceuticals Limited
 patents

Years Active: 2007-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
ENaC Inhibitors
ROR Gamma Inhibitors
PI3 Kinase Inhibitors
Oxazolidin-2-One Compounds
Heterocyclic Sulfonamide Derivatives
PDE4 Inhibitors
Azetidine Derivatives
Phenylacetamides
Pyrrolidine Derivatives
Indole Derivatives
Macrocyclic Compounds
Naphthyridine Derivatives
24 patents (USPTO):Explore Patents
1. 11739094 - Substituted benzodiazoliums as ENaC inhibitors (2023-08-29),
2. 11370778 - Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases (2022-06-28),
3. 10941149 - Substituted benzodiazoliums as ENaC inhibitors (2021-03-09),
4. 10759785 - Compounds (2020-09-01),
5. 10383850 - Indazole and indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ROR gamma) for the treatment of immune-related diseases (2019-08-20),
6. 9861612 - Indolyl-containing RORγt inhibitors (2018-01-09),
7. 9522134 - Compounds (2016-12-20),
8. 9458177 - Oxazolidin-2-one compounds and uses thereof (2016-10-04),
9. 8865894 - Oxazolidin-2-one compounds and uses thereof (2014-10-21),
10. 8822468 - 3-Methyl-imidazo[1,2-b]pyridazine derivatives (2014-09-02),
11. 8614239 - Heterocyclic sulfonamide derivatives (2013-12-24),
12. 8466289 - Heterocyclic sulfonamide derivatives (2013-06-18),
13. 8389526 - 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives (2013-03-05),
14. 8129541 - 5-phenylthiazole derivatives and use as PI3 kinase inhibitors (2012-03-06),
15. 8039455 - Macrocyclic compounds useful as BACE inhibitors (2011-10-18),

Title: Clive McCarthy: Pioneering Inventor from Basel

Introduction: Clive McCarthy is a renowned inventor based in Basel, Switzerland, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Clive McCarthy holds several patents in the areas of biotechnology, renewable energy, and artificial intelligence, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over three decades, Clive McCarthy has worked with leading research institutions and multinational companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Clive McCarthy has collaborated with top scientists, engineers, and inventors from around the world, fostering a culture of innovation and knowledge sharing.

Conclusion: Clive McCarthy's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…